AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 220.87B +39.0% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 28.32 |
| Forward PE | 17.97 |
| Dividend | 2.36 (1.66%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 2,494,407 |
| Open | 13,204 |
| Previous Close | 14,240 |
| Day's Range | 12,738 - 13,204 |
| 52-Week Range | 10,148 - 15,732 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 16,330.34 (+27.16%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 16,330p, which is an increase of 27.16% from the latest price.
News
Ionis, AstraZeneca report CARDIO-TTRansform trial misses primary endpoint
Ionis Pharmaceuticals (IONS) and partner AstraZeneca (AZN) announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not mee...
AstraZeneca says CARDIO-TTRansform trial did not meet primary efficacy endpoint
The CARDIO-TTRansform Phase III trial for AstraZeneca (AZN) and Ionis’ (IONS) Wainua in patients with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint of the co...
AstraZeneca shares plunge as Wainua fails late-stage heart disease trial
AstraZeneca shares slumped nearly 10% on Thursday after the drugmaker said its nerve disease treatment Wainua failed to achieve the primary objective in a late-stage clinical trial for a serious heart...
AstraZeneca stock dives 9% after heart drug trial misses target
AstraZeneca stock dives 9% after heart drug trial misses target
AstraZeneca Says Wainua Trial Failed to Meet Primary Goal
The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a placebo.
AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis , failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in a late-...
AstraZeneca autosomal dominant polycystic kidney disease drug gets orphan status
AstraZeneca (AZN) Pharmaceuticals’ treatment of autosomal dominant polycystic kidney disease was granted FDA orphan designation, according to a post to the agency’s website.
AstraZeneca Nears Enhertu Deal After £300 Million UK Investment
AstraZeneca Nears Enhertu Deal After £300 Million UK Investment
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports
Drugmakers AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK's pricing regulator for their breast cancer treatment Enhertu, Bloomberg News reported on Wednesday, citing multiple pe...
AstraZeneca (AZN) Secures Global Rights for COPD Treatment TQC3721
AstraZeneca (AZN) Secures Global Rights for COPD Treatment TQC3721
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal
Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.
Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
Hong Kong-listed Sino Biopharmaceutical said on Wednesday it has granted AstraZeneca the rights to develop a drug designed to treat chronic respiratory diseases outside China for total payments of...
FTSE 100 Slips as AstraZeneca and Gold Miners Offset Early Optimism
UK shares retreated as heavyweight losses outweighed easyJet's takeover rally despite resilient US services data. The post FTSE 100 Slips as AstraZeneca and Gold Miners Offset Early Optimism appeared ...
AstraZeneca price target lowered to 165 GBp from 172 GBp at HSBC
HSBC lowered the firm’s price target on AstraZeneca (AZN) to 165 GBp from 172 GBp and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC…
AstraZeneca Transcript: Investor update
Significant progress has been made in reducing emissions, expanding health equity programs, and embedding sustainability across operations and R&D. AI and digital tools drive efficiency and early intervention, while supplier engagement and sustainable product innovation support decarbonization and resilience.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on July 6, 2026.
AstraZeneca (AZN) Partners with CSPC on Kidney Disease Treatments Worth $1.77B
AstraZeneca (AZN) Partners with CSPC on Kidney Disease Treatments Worth $1.77B
AstraZeneca PLC (AZN) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 76/100
AstraZeneca PLC (AZN) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 76/100
AstraZeneca signs CSPC China deal for experimental kidney disease drugs
AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney diseases, the Chinese ...
Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Therapy
Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Therapy
Abbisko Therapeutics And AstraZeneca Enter Strategic Collaboration For Lumipodlin
(RTTNews) - Abbisko Therapeutics Co., Ltd (2256.HK), announced that it has entered into a strategic collaboration with AstraZeneca (AZN) to jointly advance the clinical development of a novel IO-TKI c...
AstraZeneca, Abbisko Therapeutics enter strategic collaboration
Abbisko Therapeutics announced that it has entered into a strategic collaboration agreement with AstraZeneca (AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for...
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreeme...
AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Tells Investors
AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Tells Investors
AstraZeneca (AZN) Faces Competition from Anthropic's New AI in Pharma Research
AstraZeneca (AZN) Faces Competition from Anthropic's New AI in Pharma Research